Drugs Made In America Acquisition Corp. Units Cash Flow Conversion Efficiency
Drugs Made In America Acquisition Corp. Units cash flow conversion efficiency. Based on the latest financial reports, Drugs Made In America Acquisition Corp. Units (DMAAU) has a cash flow conversion efficiency ratio of -0.001x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-125.18K) by net assets ($232.64 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Drugs Made In America Acquisition Corp. Units (2024–2025)
Cash flow conversion efficiency of Drugs Made In America Acquisition Corp. Units from 2024 to 2025. This chart illustrates how Drugs Made In America Acquisition Corp. Units's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Drugs Made In America Acquisition Corp. share price for real-time trading data and today's change.
Drugs Made In America Acquisition Corp. Units Cash Flow Conversion Ratio Explained
Drugs Made In America Acquisition Corp. Units cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Drugs Made In America Acquisition Corp. Units Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Drugs Made In America Acquisition Corp. Units ranked by their cash flow conversion efficiency. Also see Drugs Made In America Acquisition Corp. (DMAAU) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CapMan Oyj B
HE:CAPMAN
|
-0.087x |
|
Palmer Square Capital BDC Inc.
NYSE:PSBD
|
0.124x |
|
Sunny Friend Environmental Technology Co Ltd
TW:8341
|
0.075x |
|
Edda Wind ASA
OL:EWIND
|
0.018x |
|
TRX Gold Corporation
TO:TRX
|
0.079x |
|
Selvaag Bolig ASA
OL:SBO
|
0.106x |
|
Inmobiliaria del Sur SA
MC:ISUR
|
-0.025x |
|
SNDL INC.
F:VY4
|
0.003x |
Annual Cash Flow Conversion Efficiency for Drugs Made In America Acquisition Corp. Units (2024–2025)
The table below shows the annual cash flow conversion efficiency of Drugs Made In America Acquisition Corp. Units from 2024 to 2025. Review DMAAU cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $232.64 Million | $-539.19K | -0.002x | -100.00% |
| 2024-12-31 | $-244.85 | $-172.26K | 703.553x | -- |
About Drugs Made In America Acquisition Corp. Units
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in Fort Lauderdale, Florida.